Shattuck Labs, Inc. (STTK)
| Market Cap | 455.48M +719.7% |
| Revenue (ttm) | 1,000,000 -78.3% |
| Net Income | -49.87M |
| EPS | -0.59 |
| Shares Out | 76.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 434,705 |
| Open | 5.87 |
| Previous Close | 5.91 |
| Day's Range | 5.87 - 6.36 |
| 52-Week Range | 0.71 - 8.33 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 14.83 (+149.66%) |
| Earnings Date | Aug 13, 2026 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical... [Read more]
Financial Performance
In 2025, Shattuck Labs's revenue was $1.00 million, a decrease of -82.52% compared to the previous year's $5.72 million. Losses were -$48.81 million, -35.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for STTK stock is "Strong Buy." The 12-month stock price target is $14.83, which is an increase of 149.66% from the latest price.
News
Shattuck Labs 10.9M share Spot Secondary priced at $4.00
The deal range was $4.00-$4.25. Leerink, JPMorgan, Piper Sandler and Cantor Fitzgerald acted as joint book running managers for the offering.
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25
Leerink, JPMorgan, Piper Sandler and Cantor Fitzgerald are acting as joint book running managers for the offering.
Shattuck Labs announces common stock offering, no amount given
Shattuck Labs (STTK) announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded…
Shattuck Labs, Inc. Announces Proposed Public Offering
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-...
Shattuck Labs price target raised to $18 from $7 at Citi
Citi raised the firm’s price target on Shattuck Labs (STTK) to $18 from $7 and keeps a Buy rating on the shares. The firm doubled SL-325 probability of success to…
Shattuck Labs price target raised to $17 from $14 at Needham
Needham raised the firm’s price target on Shattuck Labs (STTK) to $17 from $14 and keeps a Buy rating on the shares after the company announced topline results for its…
Shattuck Labs Transcript: Study result
SL-325 demonstrated strong safety, durable DR3 blockade, and a low 3.7% ADA rate in phase I, supporting extended dosing and a best-in-class immunogenicity profile. A phase II Crohn's trial will launch in Q3, and the bispecific SL-846 is advancing with promising preclinical data.
Shattuck Labs Press release: Study result
Shattuck Labs issued a press release on June 8, 2026, disclosing material business information to investors.
Shattuck Labs Slides: Study result
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Shattuck Labs announces Phase 1 results for SL-325
Shattuck Labs (STTK) announced data from its Phase 1 clinical trial of SL-325, Shattuck’s lead DR3 blocking antibody candidate. Highlights included: Potentially best-in-mechanism immunogenicity profil...
Shattuck Labs Announces Phase 1 Results for SL-325
AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentia...
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-...
Citi opens ‘upside 30-day catalyst watch’ on Shattuck into data
Citi added an “upside 30-day catalyst watch” on Shattuck Labs (STTK) after upgrading the shares to Buy with a $7 price target into the Q2 Phase 1 data for SL-325…
Shattuck Labs upgraded to Buy from Neutral at Citi
Citi upgraded Shattuck Labs (STTK) to Buy from Neutral with a $7 price target The stock has sold doff roughly 30% heading into initial Phase 1 data for SL-325 in…
Shattuck Labs price target raised to $11 from $8 at Wedbush
Wedbush raised the firm’s price target on Shattuck Labs (STTK) to $11 from $8 and keeps an Outperform rating on the shares. The firm notes the company reiterated guidance for…
Shattuck Labs reports Q1 EPS (13c), consensus (13c)
As of March 31, 2026, cash and cash equivalents and short-term investments were $90.4M, vs. $60.9M as of March 31, 2025. “We are pleased to have completed enrollment in our…
Shattuck Labs sees cash and cash equivalents sufficient into 2029
06:56 EDT Shattuck Labs (STTK) sees cash and cash equivalents sufficient into 2029
Shattuck Labs Quarterly report: Q1 2026
Shattuck Labs has published its Q1 2026 quarterly earnings report on May 7, 2026.
Shattuck Labs Earnings release: Q1 2026
Shattuck Labs released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Shattuck Labs Slides: Corporate presentation
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of pote...
Shattuck Labs initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Shattuck Labs (STTK) with an Overweight rating. The stock’s more than 800% rise over the last 12 months reflects enthusiasm for its DR3 and TL1A…
Shattuck Labs price target raised to $18 from $6 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Shattuck Labs (STTK) to $18 from $6 and keeps a Buy rating on the shares. The firm increased its projected SL-325 probability…